<DOC>
	<DOCNO>NCT01150357</DOCNO>
	<brief_summary>This double-blind 8 week study evaluate dose response , efficacy ( blood pressure lower effect ) safety aliskiren child 6 - 17 year old hypertension low , mid high weight-based dos . The low dose range 6.25 mg 25 mg aliskiren , mid dose range 37.5 mg 150 mg aliskiren high dose range 150 mg 600 mg aliskiren . This study conduct support monotherapy registration aliskiren treatment hypertension child 6-17 year age .</brief_summary>
	<brief_title>Safety Efficacy Aliskiren Pediatric Hypertensive Patients 6-17 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Documented diagnosis hypertension define NHLBI 4th Report , 2004 msSBP ( mean 3 measurement ) must ≥ 95th percentile age , gender height , Visit 2 ( randomization ) measurement define NHLBI 4th Report , 2004 Patient receive immunosuppressant medication ( e.g . cyclosporine , MMF , etc ) oral/topical steroid , medical condition Current diagnosis heart failure ( NYHA Class IIIV ) history cardiomyopathy obstructive valvular disease msSBP ≥ 25 % 95th percentile Second third degree heart block without pacemaker AST/SGOT ALT/SGPT &gt; 3 time upper limit reference range Total bilirubin &gt; 2 time upper limit reference range Creatinine clearance &lt; 30 mL/min/1.73m² ( calculate use Modified Schwartz formula estimate glomerular filtration rate [ GFR ] ) , base serum creatinine concentration obtain screen visit ) WBC count &lt; 3000/mm³ Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Pediatric hypertension</keyword>
	<keyword>primary hypertension</keyword>
	<keyword>secondary hypertension</keyword>
</DOC>